ETN: GOAL II (#1173)
Laufzeit: 01.01.2021 - 31.12.2040
Kurzfassung
A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Mor208 for patients with relapsed/refractory aggressive lymphoma
Laufzeit: 01.01.2021 - 31.12.2040
A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Mor208 for patients with relapsed/refractory aggressive lymphoma
